biostudies-literatureLee KHMinistry of Science and Technology, TaiwanTaipei Veterans General Hospital751359https://www.ebi.ac.uk/biostudies/studies/S-EPMC8531471biostudies-literatureUnknown8<b>Background:</b> Oral anticoagulants (OAC) plus antiplatelets is recommended for patients with atrial fibrillation (AF) and coronary artery disease (CAD) to reduce thromboembolism. However, there is limited evidence regarding antithrombotic therapy for patients with concomitant chronic kidney disease (CKD), AF, and CAD, especially those not undergoing percutaneous coronary intervention. We aimed to use real-world data assessing the efficacy and safety of antithrombotic regimens in this population. <b>Methods:</b> We used a single-center database of 142,624 CKD patients to identify those receiving antithrombotic therapy for AF and CAD between 2010 and 2018. Patients taking warfarin or direct OAC (DOAC) alone were grouped in the OAC monotherapy (<i>n</i> = 537), whereas those taking OAC plFrontiers in cardiovascular medicineAntithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease.PMC8531471V108C-103V108D42-004-MY3-2109-2314-B-075-066V109B-016109-2314-B-010-056-MY3V109D50-001-MY3-1V109C-114Tarng DCChu YCOu SMLin YPLee KHTsai MTfalseAntithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease.<b>Background:</b> Oral anticoagulants (OAC) plus antiplatelets is recommended for patients with atrial fibrillation (AF) and coronary artery disease (CAD) to reduce thromboembolism. However, there is limited evidence regarding antithrombotic therapy for patients with concomitant chronic kidney disease (CKD), AF, and CAD, especially those not undergoing percutaneous coronary intervention. We aimed to use real-world data assessing the efficacy and safety of antithrombotic regimens in this population. <b>Methods:</b> We used a single-center database of 142,624 CKD patients to identify those receiving antithrombotic therapy for AF and CAD between 2010 and 2018. Patients taking warfarin or direct OAC (DOAC) alone were grouped in the OAC monotherapy (<i>n</i> = 537), whereas those taking OAC pl2021-01-01T00:00:00Z20212025-04-04T13:16:23.345Z2025-04-04T13:16:23.345ZS-EPMC85314713469279810.3389/fcvm.2021.751359